Form 8.3 - [Allergan Plc]
02 Dezember 2019 - 3:59PM
Dow Jones News
TIDM0Y7T TIDM0QCV
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING
1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) State Street Global Advisors &
Affiliates
--------------------------------------------- -------------------------------
Company dealt in Allergan plc
--------------------------------------------- -------------------------------
Class of relevant security to which US$0.0001 ordinary shares
the dealings being disclosed relate (Note 2)
--------------------------------------------- -------------------------------
Date of dealing 29(th) November 2019
--------------------------------------------- -------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
------------------------------------- -------------------- -----------
Number (%) Number (%)
------------------------------------- ---------- -------- ------ ---
(1) Relevant securities 15,111,480 4.60132%
------------------------------------- ---------- -------- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------- ---------- -------- ------ ---
(3) Options and agreements to
purchase/sell N/A
------------------------------------- ---------- -------- ------ ---
Total 15,111,480 4.60132%
------------------------------------- ---------- -------- ------ ---
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
------------------------------------------- ----------- -----------
Number (%) Number (%)
------------------------------------------- ------ --- ------ ---
(1) Relevant securities N/A
------------------------------------------- ------ --- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------------- ------ --- ------ ---
(3) Options and agreements to purchase/sell N/A
------------------------------------------- ------ --- ------ ---
Total N/A
------------------------------------------- ------ --- ------ ---
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
-------------- ----------------------------- -----------------------
Purchase 200 184.94
-------------- ----------------------------- -----------------------
Purchase 1,400 184.94
-------------- ----------------------------- -----------------------
Purchase 200 184.94
-------------- ----------------------------- -----------------------
Purchase 500 184.94
-------------- ----------------------------- -----------------------
Purchase 100 184.94
-------------- ----------------------------- -----------------------
Purchase 200 184.94
-------------- ----------------------------- -----------------------
Purchase 71 185.09
-------------- ----------------------------- -----------------------
Purchase 24,625 184.94
-------------- ----------------------------- -----------------------
Purchase 322 184.94
-------------- ----------------------------- -----------------------
Purchase 506 184.94
-------------- ----------------------------- -----------------------
Purchase 300 184.94
-------------- ----------------------------- -----------------------
Purchase 59 184.94
-------------- ----------------------------- -----------------------
Purchase 1,488 184.94
-------------- ----------------------------- -----------------------
Sale 691 185.13
-------------- ----------------------------- -----------------------
Sale 100 184.94
-------------- ----------------------------- -----------------------
Sale 200 184.94
-------------- ----------------------------- -----------------------
Sale 200 184.94
-------------- ----------------------------- -----------------------
Sale 200 184.94
-------------- ----------------------------- -----------------------
Sale 500 184.94
-------------- ----------------------------- -----------------------
Sale 100 184.94
-------------- ----------------------------- -----------------------
Sale 1,400 184.94
-------------- ----------------------------- -----------------------
Sale 800 184.94
-------------- ----------------------------- -----------------------
Sale 500 184.94
-------------- ----------------------------- -----------------------
Sale 6,300 184.94
-------------- ----------------------------- -----------------------
Sale 500 184.94
-------------- ----------------------------- -----------------------
Sale 1,332 184.94
-------------- ----------------------------- -----------------------
Sale 1,500 184.94
-------------- ----------------------------- -----------------------
Sale 200 184.94
-------------- ----------------------------- -----------------------
Sale 600 185.38
-------------- ----------------------------- -----------------------
Sale 151 184.94
-------------- ----------------------------- -----------------------
Sale 418 184.94
-------------- ----------------------------- -----------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
------------- --------------------- ----------------------------- --------------
N/A
------------- --------------------- ----------------------------- --------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money
e.g. call option purchasing securities to which price American, date paid/received
varying etc. the option relates European etc. per unit (Note 5)
(Note 7)
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
N/A
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
----------------- -------------------- ------------------
N/A
----------------- -------------------- ------------------
(d) Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
--------------------- ------- -------------------------
N/A
--------------------- ------- -------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person
relating to the voting rights of any relevant securities
under any option referred to on this form or relating
to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
referred to on this form is referenced. If none, this
should be stated.
-----------------------------------------------------------
N/A
-----------------------------------------------------------
Is a Supplemental Form 8 attached? (Note 9) NO
------------------------------------------------------- --------------------
Date of disclosure 02(nd) December 2019
------------------------------------------------------- --------------------
Contact name Lionel Colaco
------------------------------------------------------- --------------------
Telephone number 020 33956098
------------------------------------------------------- --------------------
If a connected EFM, name of offeree/offeror with which N/A
connected
------------------------------------------------------- --------------------
If a connected EFM, state nature of connection (Note N/A
10)
------------------------------------------------------- --------------------
(END) Dow Jones Newswires
December 02, 2019 09:44 ET (14:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
